CoChat

Human chimeric antigen receptor macrophages for cancer immunotherapy

Open access

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic malignancies, but its application to solid tumors has been challenging 1-4. Given the unique effector functions of macrophages and their capacity to penetrate tumors 5, we genetically engineered human macrophages with CARs to direct their phagocytic activity against tumors. We found that a chimeric adenoviral vector overcame the inherent resistance of primary human macrophages to genetic manipulation and imparted a sustained pro-inflammatory (M1) phenotype. CAR macrophages (CAR-Ms) demonstrated antigen-specific phagocytosis and tumor clearance in vitro. In two solid tumor xenograft mouse models, a single infusion of human CAR-Ms decreased tumor burden and prolonged overall survival. Characterization of CAR-M activity showed that CAR-Ms expressed pro-inflammatory cytokines and chemokines, converted bystander M2 macrophages to M1, upregulated antigen presentation machinery, recruited and presented antigen to T cells and resisted the effects of immunosuppressive cytokines. In humanized mouse models, CAR-Ms were further shown to induce a pro-inflammatory tumor microenvironment and boost anti-tumor T cell activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41587-020-0462-y

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 1,495

Metadata

Authors
Klichinsky, M., Ruella, M., Shestova, O., Lu, X. M., Best, A., Zeeman, M., Schmierer, M., Gabrusiewicz, K., Anderson, N. R., Petty, N. E., Cummins, K. D., Shen, F., Shan, X., Veliz, K., Blouch, K., Yashiro-Ohtani, Y., Kenderian, S. S., Kim, M. Y., O’Connor, R. S., Wallace, S. R., Kozlowski, M. S., Marchione, D. M., Shestov, M., Garcia, B. A., June, C. H., & Gill, S.
Affiliations
  • Carisma Therapeutics (United States) (US)
  • University of Pennsylvania (US)
  • Mayo Clinic (US)
  • Washington University in St. Louis (US)
Corresponding author
Gill, Saar
Venue
Nature Biotechnology
Published
2020-03-23
Volume
38
Issue
8
Pages
947-953
ISSN
  • 0733-222X (ISSN-L)
  • 1087-0156
  • 1546-1696
OpenAlex
W2913136103
Cited by
1,495
References
37
Citations by year
2026: 257 · 2025: 261 · 2024: 294 · 2023: 242 · 2022: 204 · 2021: 171 · 2020: 65
FWCI
61.93
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Biotechnology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Scholarly Commons (University of Pennsylvania) (submittedVersion)
Funders
  • Penn | Perelman School of Medicine at the University of Pennsylvania | Abramson Family Cancer Research Institute
  • Carisma Therapeutics Inc. [Sponsored Research Agreement]
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
chimeric antigen receptor macrophages, macrophage engineering, solid tumors, cancer immunotherapy, adenoviral vector, M1 macrophage polarization, phagocytosis, tumor microenvironment, antigen presentation, T cell activation, immunosuppressive cytokines, humanized mice, xenograft models
MeSH terms
Animals, Cell Survival, Humans, Immunotherapy, Lung Neoplasms, Macrophages, Neoplasms, Neoplasms, Experimental, Immunotherapy, Adoptive, Microscopy, Video, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Human chimeric antigen receptor macrophages for cancer immunotherapy. https://app.cochat.ai/papers/10.1038/s41587-020-0462-y
The paper
Klichinsky, M., Ruella, M., Shestova, O., Lu, X. M., Best, A., Zeeman, M., Schmierer, M., Gabrusiewicz, K., Anderson, N. R., Petty, N. E., Cummins, K. D., Shen, F., Shan, X., Veliz, K., Blouch, K., Yashiro-Ohtani, Y., Kenderian, S. S., Kim, M. Y., O’Connor, R. S., . . . Gill, S. (2020). Human chimeric antigen receptor macrophages for cancer immunotherapy. Nature Biotechnology. https://doi.org/10.1038/s41587-020-0462-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.